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Scope: Cruciferous-rich diets have been associated with reduction in plasma LDL-cholesterol
(LDL-C), which may be due to the action of isothiocyanates derived from glucosinolates that
accumulate in these vegetables. This study tests the hypothesis that a diet rich in high gluco-
raphanin (HG) broccoli will reduce plasma LDL-C.
Methods and results: One hundred and thirty volunteers were recruited to two independent
double-blind, randomly allocated parallel dietary intervention studies, and were assigned to
consume either 400 g standard broccoli or 400 g HG broccoli per week for 12 weeks. Plasma
lipids were quantified before and after the intervention. In study 1 (37 volunteers), the HG
broccoli diet reduced plasma LDL-C by 7.1% (95% CI: –1.8%, –12.3%, p = 0.011), whereas
standard broccoli reduced LDL-C by 1.8% (95%CI+3.9%, –7.5%, ns). In study 2 (93 volunteers),
theHG broccoli diet resulted in a reduction of 5.1% (95%CI: –2.1%, –8.1%, p= 0.001), whereas
standard broccoli reduced LDL-C by 2.5% (95% CI: +0.8%, –5.7%, ns). When data from the
two studies were combined the reduction in LDL-C by the HG broccoli was significantly greater
than standard broccoli (p = 0.031).
Conclusion: Evidence from two independent human studies indicates that consumption of
high glucoraphanin broccoli significantly reduces plasma LDL-C.
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1 Introduction
Human intervention studies have provided evidence that di-
ets rich in cruciferous vegetables may modify plasma lipid
and cholesterol profiles [1–5]. At a population level, a 1% re-
duction in LDL-cholesterol (LDL-C) has been associated with
a 1–2% reduction in risk of coronary artery disease [6]. Recent
studies have also highlighted the requirement for cholesterol
by cancer cells [7], which have led to a growing interest in the
use of statins as cancer therapeutic agents [8]. Thus, a reduc-
tion in LDL-C by cruciferous vegetables may contribute to the
putative health promoting properties of these vegetables.
We have previously described the development of broc-
coli cultivars that have enhanced expression of the Myb28
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transcription factor due to introgression of a novel Myb28
allele from the wild species Brassica villosa. The presence of
a single Myb28 villosa allele results in a threefold greater
accumulation of 4-methylsulphinylbutyl glucosinolate [‘glu-
coraphanin’], the precursor of the potent nuclear factor
[erythroid-derived 2]-like 2 (nrf2) inducer, sulforaphane, com-
pared to that within standard broccoli cultivars [9]. As these
‘high glucoraphanin’ (HG) cultivars are identical in appear-
ance and other nutritional components to standard broccoli
cultivars [9] they enable blinded human intervention studies
to explore the role of glucoraphanin on biomarkers of health.
We have previously reported that consumption of HG broc-
coli results in enhanced nrf2-mediated transcription in hu-
man gastric biopsies compared to consumption of standard
broccoli [10], and that consumption of 400 g HG broccoli
each week over a 12 week period affected plasma metabo-
lites in a manner consistent with improved integration of
fatty acid -oxidation and TCA cycle activity withinmitochon-
dria, probably due to modulation of cellular redox status [11].
However, while we observed significant changes in plasma
lipid and steroid metabolites in this previous study, the re-
duction in LDL-C by the HG broccoli was not significantly
greater than that observed with the standard broccoli [11].
Here, we provide more detailed analyses of the changes in
plasma lipids in this first study, and report a second larger di-
etary intervention study of near identical design to test the hy-
pothesis that consumption of 400 g/week of HG broccoli for
12weekswould significantly reduce plasmaLDL–Ccompared
with standard broccoli. We additionally investigate whether
there is any association between the broccoli consumption
and genotype at glutathione transferase M1(GSTM1), poly[A]
polymerase gamma (PAPOLG) and apolipoprotein E (APOE)
loci all of which have been associated with diet-gene interac-
tions [11–13].
2 Materials and methods
2.1 Study 1
The study design and details of recruitment has been pre-
viously reported [11]. Briefly, male and female volunteers
aged 50–77 years were recruited from within a 40 mile ra-
dius of the city of Norwich, United Kingdom who had a
10 year cardiovascular risk profile of between 10 and 20%,
estimated using the JBS2 CVD risk assessor [14]. Volunteers
were required to consume 400 g of HG broccoli or 400 g of
a standard broccoli [cultivar Ironman] for 12 weeks, with-
out any other dietary restrictions. The two broccoli geno-
types, which looked identical, were coded by a third party,
and their identity was not known to the study volunteers
and investigators until completion of data collection. The
HG broccoli contained 21.6 ± 1.60 mol/g dry weight glu-
coraphanin (4-methylsulphinylbutyl glucosinolate) and 4.5 ±
0.34mol/g dryweight glucoiberin (3-methylsulphinylpropyl
glucosinolate), whereas the standard broccoli contained
6.9 ± 0.44 mol/g dry weight glucoraphanin and 0.7 ±
0.33 mol/g dry weight glucoiberin. There were no dif-
ferences in the concentrations of indole glucosinolate be-
tween the two types of broccoli. The broccoli was grown and
harvested with standard agronomic practices. Heads were
floreted, blanched and frozen (–20C) with standard com-
mercial procedures [11]. Total cholesterol (TC), high density
lipoprotein-cholesterol (HDL-C) and triacylglycerol (TAG)
were analysed in fasted blood samples immediately before
and after the dietary intervention, as previously described
[11].
2.2 Study 2
2.2.1 Participants
Men andwomenwere enrolled into the second study between
August 2012 and October 2013. Participants with a 10 year
cardiovascular risk profile of between 10 and 30% estimated
using the JBS2 CVD risk assessor [14] were eligible to par-
ticipate in the study. Those who were aged <50 years, had
suffered a stroke, myocardial infarction or transient ischemic
attack, had a BMI of <20 or >40, a diagnosis of diabetes
or a fasting glucose level of >6 mmol/L, a blood pressure >
160/90mmHg, a fasting cholesterol> 8mmol/L,were on any
form ofmedication known to affect the cardiovascular system
or who were diagnosed with chronic kidney disease were ex-
cluded. Those that satisfied the above criteria, ascertained at
an eligibility screening appointment, entered the study after
informed consent was obtained. Participants were asked to
continue any permitted prescribed medication for the dura-
tion of the trial and to inform the investigators of any changes
in medication. Participants on certain supplements (includ-
ing glucosamine and cod liver oil) were asked to discontinue
use for at least five weeks prior to starting the intervention.
The study was approved by the Institute of Food Research’s
HumanResearchGovernanceCommittee (Ref: IFR01/2012),
Norfolk Research Ethics Committee (Ref: 12/EE/0313), NHS
Norfolk & Waveney Research Governance Committee (Ref:
2012GP17 (104550)), The University of Reading Research
Ethics Committee (Ref: 12/32) and as the study was adopted
onto the National Institute for Health Research Clinical Re-
search Network [NIHR CRN] Portfolio, approval was also ob-
tained from the NIHR coordinated System for Gaining NHS
Permission (Ref: 12635). The study is registered at clinical-
trials.gov (registration ID no. NCT01929564) and conducted
according to the Declaration of Helsinki.
2.2.2 Sample size
Sample size was estimated based on the following consid-
erations. The previous study that evaluated the effects of
consumption of 400 g/week of HG broccoli diet on lipid
profile, showed that there was no statistically different effect
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Figure 1. Change in LDL-C fol-
lowing dietary intervention with
standard broccoli [-] or high glu-
coraphanin broccoli [+]. Each
panel shows the mean and 95%
CI for the change in LDL-C as
evident from paired t-tests be-
tween the baseline and post in-
tervention LDL-C for each in-
dividual within the two dietary
arms, and an ANOVA for the dif-
ference based upon a general
linear model [Table 3]. (A) Study
1 (B) Study 2. (C) Combined data
from Study 1 and Study 2.
of the HG broccoli diet on TC, LDL-C or HDL-C compared to
standard broccoli [11], but suggested a difference may be ap-
parent with a larger study (Fig. 1A). The data on LDL-C esti-
mated a minimum sample size of 48 participants per arm for
this current study, thus a total of 96 participants was predicted
to be required. This calculation was based on four assump-
tions: [a] The mean baseline concentration of LDL-C of the
total recruited population would equal 3.77 mmol/L and the
interparticipant standard deviationwould equal 0.39mmol/L,
[b] the change due to the HG broccoli would be 0.20 mmol/L,
while the mean of the standard broccoli group will remain
constant at 3.77 mmol/L, [c] a significance level of 0.05 for
80% power and [d] the study is one-tailed test.
2.2.3 Intervention
Male and female participants aged 50–76 years were recruited
fromwithin a 40mile radius of the Institute of Food Research
inNorfolk and theUniversity of Reading in Berkshire, United
Kingdom. A combination of participant databases, GP surg-
eries, distributed flyers/poster and word of mouth were used
for recruitment. Participants were recruited during the pe-
riod of August 2012 and October 2013 on the basis of a fasted
[8 h] screening blood and urine sample, the completion
of an eligibility questionnaire and their risk score calculated
using the JBS2 algorithm [12]. A double-blind, 12 week ran-
domized two-arm parallel study was then undertaken with
men and women who after screening were judged to be
at mild or moderate risk of CV, based upon the JBS2 risk
estimator (10–30% risk score), as described above. Partici-
pants were required to consume 400 g of HG broccoli or 400
g of a standard broccoli cultivar as part of their habitual diet
for 12 weeks, without any other dietary restrictions. The two
broccoli genotypes were coded by a third party and their iden-
tity was not known to the study investigators or participants
until completion of data collection and analyses. Participants
were randomised centrally as they were recruited by a min-
imisation program [minim] [15] stratified by age, sex, BMI,
smoking status and plasma LDL-C concentrations, to min-
imise any differences between the treatment groups over the
two sites.
The development and phenotypic analysis of HG broccoli
has been reported previously [9]. Briefly,HGbroccoli contains
a Myb28 transcription factor, introgressed by conventional
breeding from the wild species B. villosa, which results in
enhanced assimilation of sulphate and channelling of the ad-
ditional sulphur to glucoraphanin [9]. Previous studies have
reported the pharmacokinetics of sulforaphane metabolism
in human volunteers following consumption of standard and
HG broccoli [16]. The standard broccoli [cultivar Parthenon]
and the HG broccoli (hybrid 1199) were grown and harvested
by Seminis in Boston Lincolnshire, with the use of stan-
dard agronomic procedures. Heads were harvested, floreted,
blanched and frozen (–20C) as described previously using
standard commercial practice [11]. Following processing, the
HG broccoli contained 24.83 ± 1.19 mol/g dry weight glu-
coraphanin and 5.67 ± 0.40 mol/g dry weight glucoiberin,
whereas the standard broccoli contained 9.47 ± 0.25 mol/g
dry weight glucoraphanin and 1.77± 0.12mol/g dry weight
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glucoiberin. There were no differences in the concentrations
of indole glucosinolate between the two broccoli cultivars.
The frozen broccoli was delivered to the participants in their
homes every 3 to 6 weeks, or was collected by the participants
from their nearest study centre. Participants prepared the
broccoli cultivars from frozen by steaming for up to 5 min,
having been provided with a steamer, written instructions
and a cooking demonstration.
This study required 96 participants in total recruited over
both sites with an equal split for the standard and HG broc-
coli group. Participants were requested to avoided caffeine
for 24 h, excessive exercise for 12 h and fast for at least 8 h
prior to their study visit at their local centre [either Human
Nutrition Unit, Institute of Food Research Norwich or Hugh
Sinclair Unit of Human Nutrition, University of Reading].
Participants were asked to attend two study visits pre- and
post-intervention. On arrival at the unit a blood sample was
taken by venepuncture, following this an ambulatory blood
pressure monitor (Spacelabs 90207, Spacelabs Healthcare,
USA) was used to measure the participants’ systolic and dias-
tolic blood pressure every ten minutes for an hour while they
rested supine in a quiet room.
2.2.4 Plasma biomarkers and statistical analyses
Fasted blood samples were centrifuged at 1800× g for 15min
at 20C (for serum) and 4C (for plasma), and stored at−80C.
Total cholesterol, high density lipoprotein-cholesterol and tri-
acylglycerol were quantified using an autoanalyzer [reagents
and analyzer: Instrumentation Laboratory Ltd., Warrington,
UK] at the University of Reading. The concentration of LDL
was calculated using the Friedewald equation [17]. Paired t-
tests with 95% confidence intervals were used to analyse the
change in LDL-C, TC, HDL-C and TAG within the two arms
of each of the studies, and ANOVA-General Linear Model
was used to compare the changes between arms in LDL-C,
TC, HDL-C and TAG and to quantify the effect of study,
recruitment centre, sex and GSTM1, PAPOLG and APOE
genotypes.
2.2.5 Dietary intake analysis
Participants completed weekly tick sheets during the 12-week
intervention period to identify when the portions of the broc-
coli were eaten. Every four weeks, participants were contacted
by telephone and asked about adherence to the diet. A 7-day
estimated food intake diet diarywas completed by participants
at baseline and after 10 weeks using household measures as
an indication of portion size. Participants were instructed
by study scientists how to assess portion size and complete
the diaries. On completion, the diaries were checked for com-
pleteness with quantities verifiedwith the participant, prior to
being sent to the University of Reading for analysis. Food in-
take information from the diaries was assessed by Diet Plan6
(Forest Software, West Sussex) and analysed for differences
in nutrient composition between the intervention groups at
baseline and 10 weeks after the start of the intervention with
ANOVA.
2.3 SNP genotype analysis
GenomicDNAsampleswere isolated from the blood of volun-
teers byusing theQIAGENDNeasyBlood&Tissue kit accord-
ing to manufacturer’s instructions. DNA samples were geno-
typed for the SNPs rs74837985 (GSTM1, #C_44202997_20),
rs28459296 (PAPOLG, #C_62181387_10), rs7412 (APOE,
#C_904973_10) and rs429358 (APOE, #C_3084793_20) using
predesigned TaqMan R© SNP Genotyping Assays (Life Tech-
nologies) on an Applied Biosystems R© StepOnePlusTM Real-
Time PCR System. APOE alleles 2–4 were determined from
the genotype combination of rs7412 and rs429358 [18].
3 Results
3.1 Study 1
Participant recruitment and dietary intake analyses have been
previously reported [11]. Pre- and post-plasma lipid data were
obtained from 19 volunteers on the standard broccoli diet and
18 volunteers on the HG broccoli diet.
3.2 Study 2—Participant recruitment
Of the 510 participantswho attended introductory talks across
both study sites, 424 were screened and 107 were recruited
onto the study. Of these, eight withdrew for personal rea-
sons, one withdrew due to a protracted illness, one was pre-
scribed blood pressure medication by their clinician and was
withdrawn, one developed an allergy to the ambulatory blood
pressure cuffs and we were unable to obtain blood from one.
In total 93 participants completed the study of which 45 par-
ticipants were allocated to HG broccoli and 48 to standard
broccoli (Supporting Information Fig. 1, Table 1). All women
were either post- or peri-menopausal. All participants com-
pleted theweekly tick sheet, all of whichwere 100% compliant
with the dietary intervention.
3.2.1 Study 2—Dietary intake analysis
There were no significant differences between dietary com-
ponents either between the two arms of the study or between
the two dietary assessments for each individual except for
% energy (E) carbohydrate which was higher after the HG
broccoli compared with the standard broccoli (p = 0.003), al-
though there were no differences in the %E sugars or %E
starch (Supporting Information Table 1).
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Table 1. Baseline characteristics of volunteers for Study 2
High glucoraphanin broccoli Standard broccoli
Male (n = 28) Female (n = 19) Male (n = 27) Female (n = 21)
Age (y) 60.2 ± 6.38a) 63.0 ± 5.72 59.8 ± 5.49 63.5 ± 7.09
BMI (kg/m2) 26.7 ± 3.43 26.0 ± 4.70 27.5 ± 3.67 26.3 ± 4.20
Systolic BP (mmHg) 128.1 ± 14.80 128.4 ± 12.9 126.3 ± 11.24 134.1 ± 10.84
Diastolic BP (mmHg) 83.1 ± 9.87 76.9 ± 10.20 81.6 ± 7.51 78.9 ± 6.10
Weight (kg) 83.4 ± 13.06 68.9 ± 10.14 86.5 ± 12.35 68.0± 12.25
Waist circumference (cm) 98.7 ± 11.20 87.6 ± 11.73 100.5 ± 8.66 87.2 ± 11.50
Hip circumference (cm) 105.5 ± 6.25 107.0± 8.66 106.8 ± 6.95 105.3 ± 10.17
Total cholesterol (mmol/L) 5.9 ± 0.86 6.7 ± 0.71 5.8 ± 0.96 6.7 ± 0.90
LDL cholesterol (mmol/L) 4.2 ± 0.71 4.6 ± 0.77 4.1 ± 0.79 4.7 ± 0.80
HDL cholesterol (mmol/L) 1.4 ± 0.28 1.8 ± 0.32 1.4 ± 0.31 1.7 ± 0.29
Triglycerides (mmol/L) 1.6 ± 0.69 1.1 ± 0.32 1.5±0.57 1.2 ± 0.30
Glucose (mmol/L) 5.7 ± 0.47 5.7 ± 0.46 5.7 ± 0.43 5.7 ± 0.48
JBS2 CVD risk score (%) 17.5 ± 5.85 14.4 ± 4.89 17.1 ± 5.54 12.5 ± 2.52
a) All values are mean ± SD.
3.3 SNPs
The frequency of theAPOE2, APOE3 andAPOE4 alleles were
6.7, 73.9 and 19.3% that are not significantly different from
that previously reported in Caucasian population (2 = 2.84,
p = 0.242) [13]. At baseline, individuals with the E4/E4 geno-
type had significantly greater levels of TC and LDL-C than
those individuals with E2/E3 genotype (Table 2). The fre-
quency of the PAPOLG A and G alleles and the GSTM1 null
genotype were similar to that previously reported [11]. There
was no association between PAPOLG and GSTM1 genotype
and plasma TC, LDL-C or TAG levels.
3.4 Plasma lipid and cholesterol profiles
In study 1, volunteers consuming theHG broccoli had signif-
icant reduction in plasma LDL-C compared to their own base-
line level (Fig. 1A), but with no significant changes inHDL-C,
TC or TAG (Supporting Information Figs. 2–4). Near identi-
cal results were obtained in study 2, in which volunteers con-
suming the HG broccoli had significant reductions in LDL-C
(Fig. 1B). When data from the two studies were combined,
the reduction in LDL-C by the HG broccoli was significantly
greater (p = 0.031) than that of the standard broccoli (Fig.
1C, Table 3). There was no significant association between
Table 3. ANOVA—General linear model for the variation in LDL-C
Source DF Seq SS Adj SS Adj MS F p
Broccoli gluco-
raphanin
phenotype a
1 566.0 527.3 527.3 4.78 0.031
Study 1 25.8 16.4 16.4 0.15 0.701
Recruitment
centre
1 6.4 12.7 12.7 0.12 0.735
Sex 1 124.7 60.1 60.1 0.55 0.462
APOE genotype 5 219.8 168.2 33.6 0.30 0.909
PAPOLG
genotype
2 117.4 123.0 61.5 0.56 0.574
GSTM1
genotype
1 22.4 22.4 22.4 0.20 0.653
Error 107 11802.4 11802.4 110.3
Total 119 12884.9
a) HG, high glucoraphainin broccoli is heterozygous for
Myb28villosa allele and a Myb28broccoli allele. Standard gluco-
raphanin broccoli is homozygous for Myb28broccoli alleles.
reduction in LDL-C and study, recruitment centre, sex or
genotype (Table 3).
The reduction in LDL-CbyHGbroccoli was not dependent
upon baseline LDL levels (% LDL-C = 5.8–2.6LDL-Cbaseline,
r2 = 2.9%, p = 0.097), in contrast to that of standard broccoli
Table 2. APOE genotype frequency and baseline plasma cholesterol and triacylglycerol levels
Frequency (%) Total C LDL-C HDL-C Triacylglycerol
E2/E3 11 5.1 ± 1.04a) 3.5 ± 0.87 1.3 ± 0.25 1.5 ± 0.63
E2/E4 2 5.3 ± 0.86 3.5 ± 0.21 1.5 ± 0.66 1.4 ± 0.43
E3/E3 55 6.2 ± 0.86 4.3 ± 0.75 1.6 ± 0.31 1.2 ± 0.43
E3/E4 28 6.2 ± 0.97 4.3 ± 0.75 1.6 ± 0.41 1.4 ± 0.64
E4/E4 4 7.0 ± 0.91b) 5.0 ± 0.87b) 1.7 ± 0.22 1.3 ± 0.65
a) All values are means ± SD.
b) E4/E4 genotypes have significantly greater Total-C and LDL-C than E2/E3 genotypes [p = 0.001, ANOVA].
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Figure 2. The mean and 95% CI
for the change in LDL-C from
paired t-tests between the base-
line and postintervention LDL-
C for each individual within the
two dietary arms within sub-
groups with different baseline
LDL-C. The data combines that
of the current study with that of
Armah et al. [2014].
that was significantly associated (% LDL-C = 18.8–4.8LDL-
Cbaseline, r2 = 13.7%, p = 0.001). Thus, once we reanalyse data
according to subgroups of volunteers with different base-
line LDL-C we observed a more moderate effect of standard
broccoli at reducing LDL-C but only in volunteers who have
higher baseline LDL-C (Fig. 2). There was some evidence,
as expected, that HG broccoli would also reduce TC, but no
evidence of any effect on HDL-C or TAG [Supporting In-
formation Figs. 2–4]. Likewise, there was no evidence of an
interaction between genotype and change in TC, HDL-C or
TAG (Supporting Information Tables 2–4).
4 Discussion
Several previous human intervention studies with broccoli
sprouts, Brassica extracts or mixed vegetable interventions
that include crucifers have reported a reduction in LDL-C
[1–5]. Furthermore, transfer of sheep from grazing grass to
Brassica forage results in a reduction in plasma cholesterol
[19]. While HG broccoli reduced plasma LDL-C to a greater
extent that standard broccoli (Table 3), there is some indica-
tion that consuming standard broccoli may also be reducing
plasma LDL-C, although in neither study 1 or 2, nor through
combining the two studies is the reduction significantly dif-
ferent from baseline (p > 0.05). To ascertain the effect of
standard broccoli on LDL-C would require a larger study.
This however indicates that the reduction in LDL-C is due to
the metabolic activity of glucoraphanin, as this is the major
difference between the HG and standard broccoli.
The probable mechanism by which glucoraphanin re-
duces LDL-C is through the induction of nrf2-antioxidant
response element mediated transcription by sulforaphane
derived from glucoraphanin. Several animal studies suggest
that nrf2 expression is closely associated with modulating
mitochondrial fatty acid oxidation and lipid and steroid syn-
thesis [20–23]. The two major signalling pathways that medi-
ate cellular metabolism, PI3K signalling and AMP-activated
protein kinase (AMPK) signalling, antagonistically regulate
lipid and steroid biosynthesis and are both sensitive to regu-
lation through the redox status of the cells and tissues. PI3K
signalling enhances expression of sterol regulatory element-
binding proteins (SREPBs) resulting in cholesterol synthesis
[24–26], but is itself negatively regulated by phosphatase and
tensin homolog (PTEN). In amore oxidising cellular environ-
ment, PTEN becomes inactivated, but is reactivated following
disulphide bond reduction mediated by thioredoxin [27–31].
Thus, enhanced activity of thioredoxin reductase and supply
of NADPH via the pentose phosphate pathway resulting from
enhanced nrf2 mediated transcription may lead to activation
of PTEN and concomitant down regulation of PI3K signalling
and lipid and sterol synthesis. AMPK activity, in contrast,
suppresses cholesterol biosynthesis through inhibition of
acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA
reductase, and enhances fatty acid  oxidation [32]. However,
AMPK is also redox sensitive and its activity is inhibited in a
more oxidising cellular environment through oxidation and
intermolecular disulphide bond formation, but is reactivated,
in a similar manner to PTEN, by thioredoxin [33]. Thus, it
is possible that diets rich in HG broccoli are able to reduce
plasma LDL-C through modulating the redox status of cells
and tissues resulting in enhanced activity of AMPK signalling
and suppression of PI3K signalling.
More extreme forms of the phenotypic effect of nrf2 in-
duction on lipid and cholesterol synthesis are reported in ani-
mal model systems in which the nrf2 inducers sulforaphane,
oltipraz and the synthetic triterpenoid CDDO-imidazolide
have each been shown to prevent obesity in mice fed high
fat diets [20, 34, 35], an effect that is reduced in nrf2 knock-
outmice [34]. Furthermore, constitutive overexpression of the
nrf2 ortholog SKN-1 prevents fat accumulation inCaenorhab-
ditis elegans when fed a high carbohydrate diet [36].
The inhibition of cholesterol synthesis via nrf2-mediated
redox regulation of signalling pathways would be consis-
tent with the putative anticarcinogenic activity of cruciferous
vegetables, in which maintenance of PTEN and AMPK ac-
tivity would be expected to suppress cell proliferation and
carcinogenesis [37].
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Brassica vegetables are also dietary sources of S-
methylcysteine sulfoxide (SMCSO) [38] that has been shown
to reduce plasma LDL-C levels when administered to rodents
[39, 40]. However, the level of SMCSO in HG broccoli is ap-
proximately 20% less than in standard broccoli [9], and thus
unlikely to explain the greater ability of the HG broccoli to
reduce LDL-C compared to standard broccoli, although may
still contribute to reducing plasma LDL-C levels by both broc-
coli genotypes. Likewise, there is no difference in the level of
fibre between the broccoli genotypes [9], which may also con-
tribute to reducing LDL-C levels. Other compounds, such as
phytosterols may also have a role in reducing cholesterol, but
due to the very limited introgression of the B. villosa genome
into the broccoli genome [9], are unlikely to vary between the
contrasting Myb28 genotypes.
It is also noteworthy that the reductions in LDL-C were
due to consumption of broccoli that had been blanched and
frozen. The blanching process destroys all endogenous plant
thioglucosidase [‘myrosinase’] activity that is required to con-
vert glucoraphanin to the nfr2 inducer sulforaphane. Several
studies have reported that this conversion can also occur due
to the activity of the gut microbiota [41, 42], but with much
less efficiency than if plant myrosinase is active. Thus, it is
possible that consuming cooked fresh broccoli that retains a
small myrosinase activity that can generate higher amounts
of sulforaphane in the GI tract compared to gut micobiota-
derived isothiocyanates [43], may have a more pronounced
effect on reducing LDL-C than that reported in the current
study.
There was a significant association between APOE geno-
type with baseline LDL-C, with higher levels associated with
the E4 allele and lower levels with the E2 allele, consistent
with previous reports (Table 2) [13, 44]. However, there was
no evidence of an interaction between APOE genotype and
diet on LDL-C levels (Table 3), as has also been previously
reported for the effect of dietary fat on LDL-C [13], or interac-
tions with GSTM1 and PAPOLG genotype (Table 3).
This proposed mode of action for LDL-C reduction con-
trasts with that of other known dietary components and phar-
maceuticals that reduce LDL-C. Oat  glucans have been
shown to reduce LDL-C by a similar extent to the HG broc-
coli described in the current study [45–47]. This reduction
is likely to be due to reduced intestinal bile acid reabsorp-
tion leading to enhanced bile acid synthesis and a resul-
tant reduction in plasma LDL-C [48]. Plant stanols have also
been shown to reduce plasma LDL-C by between 7 and 10%
[49]. These cholesterol-like molecules probably prevent up-
take of cholesterol in the intestinal tract butmay also interfere
with cholesterol metabolism. Statins, which are now widely
prescribed to reduce LDL-C, specifically inhibit 3-hydroxy-3-
methylglutaryl-coenzyme A, a key enzyme in cholesterol syn-
thesis. These drugs can reduce LDL-C by 20–45% depending
upon dosage and the specific drug [50], with beneficial effects
even for people who are at low risk of vascular disease [51].
In conclusion, evidence is provided that broccoli consump-
tion may result in reduction in plasma LDL-C levels. This is
likely to be due to a combination of dietary components found
within broccoli, including glucoraphanin, fibre and SMCSO.
HG broccoli reduces LDL-C to a greater extent than standard
broccoli, and to a similar amount to that following intake of
oat  glucans and plant stanols. This is likely to be due to the
higher levels of glucoraphanin. Themechanismbywhich this
reduction occurs is consistent with the inhibition of choles-
terol synthesis as suggested by studies with animal models
[20, 22], as opposed to suppression of cholesterol or bile acid
absorption. If this is the case, it is possible that combining
broccoli with other dietary components that inhibit absorp-
tion may have an additive effect on the reduction of plasma
LDL-C.
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